Piramal Pharma is currently trading at Rs. 210.30, up by 5.55 points or 2.71% from its previous closing of Rs. 204.75 on the BSE.
The scrip opened at Rs. 203.50 and has touched a high and low of Rs. 211.50 and Rs. 201.70 respectively. So far 341679 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 218.40 on 10-Aug-2026 and a 52 week low of Rs. 132.50 on 23-Mar-2026.
Last one week high and low of the scrip stood at Rs. 216.90 and Rs. 201.70 respectively. The current market cap of the company is Rs. 27845.15 crore.
The promoters holding in the company stood at 34.80%, while Institutions and Non-Institutions held 27.09% and 38.11% respectively.
Piramal Pharma has completed acquisition of additional 40.67% stake in Yapan Bio, comprising 1,46,400 equity shares of Rs 10 each, from its existing shareholders for an aggregate cash consideration of around Rs 76 crore. Pursuant to the acquisition, the company's shareholding in Yapan has increased from 33.33% to 74.00% of the equity share capital of Yapan. Consequent to the above acquisition, Yapan has ceased to be an associate company and has become a subsidiary of the Company.
With this acquisition, PPL will fully embed Yapan’s advanced large molecule capabilities into its integrated service offering, enabling the company to develop and scale complex biologic therapies with greater efficiency.
Piramal Pharma provides end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
